SNWV

+ Watchlist + Portfolio

SANUWAVE Health, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.62
52-Week Range: $3.92 – $40.87
Market Cap: $41.46M
P/E (TTM): 20.08
EPS (TTM): 0.24
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 14.88
PEG Ratio: —
Return on Equity: —
Return on Assets: 5.51%
Gross Margin: 76.33%
Operating Margin: -2.88%
Profit Margin: 34.66%
Current Ratio: 1.28
Debt/Equity: 7.43
Total Debt: $20.71M
Free Cash Flow: $-2.83M
Revenue Growth: -3.10%
Earnings Growth: —
Enterprise Value: $52.79M

SNWV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$16.74M	$20.40M	$32.63M	$44.05M
Cost of Revenue	$4.33M	$6.04M	$8.08M	$10.08M
Gross Profit	$12.41M	$14.36M	$24.55M	$33.97M
Research & Development	$567.00K	$579.00K	$673.00K	$1.35M
Selling, General & Admin	$20.03M	$13.57M	$19.24M	$26.79M
Operating Expenses	$21.36M	$14.90M	$20.70M	$29.02M
Operating Income	-$8.95M	-$540.00K	$3.85M	$4.95M
EBITDA	$4.79M	-$9.15M	-$18.13M	$19.43M
Pretax Income	-$10.29M	-$25.80M	-$33.06M	$11.90M
Income Tax	$2.00K	$4.00K	$27.00K	$86.00K
Net Income	-$10.29M	-$25.81M	-$33.08M	$11.81M
Diluted EPS	-7.50	-12.19	-7.03	0.41
Diluted Shares	1.47M	2.12M	4.46M	9.08M

SNWV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.15M	$1.80M	$10.24M	$11.96M
Receivables	$4.03M	$3.31M	$3.33M	$5.42M
Inventory	$868.00K	$2.95M	$4.15M	$5.93M
Current Assets	$6.62M	$9.78M	$18.40M	$24.63M
Total Assets	$19.87M	$22.42M	$30.12M	$37.34M
Current Liabilities	$60.22M	$64.75M	$45.42M	$17.85M
Long-Term Debt	—	—	—	$16.32M
Total Debt	$38.98M	$30.45M	$25.80M	$22.97M
Total Liabilities	$60.88M	$65.59M	$45.91M	$35.72M
Retained Earnings	-$194.24M	-$220.05M	-$254.50M	-$242.69M
Shareholders' Equity	-$41.01M	-$43.18M	-$15.79M	$1.62M
Working Capital	-$53.59M	-$54.97M	-$27.03M	$6.78M
Net Debt	$37.38M	$28.16M	$15.07M	$10.00M

SNWV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.17M	-$4.54M	$2.46M	$3.88M
Capital Expenditure	—	—	-$490.00K	-$1.94M
Free Cash Flow	-$17.17M	-$4.54M	$1.97M	$1.93M
Depreciation & Amortisation	$952.00K	$1.03M	$1.15M	$1.28M
Stock-Based Compensation	—	$0.00	$1.51M	$4.85M
Investing Cash Flow	$332.00K	$21.00K	-$490.00K	$3.43M
Financing Cash Flow	$17.38M	$5.21M	$6.35M	-$5.59M
Net Change in Cash	$547.00K	$694.00K	$8.32M	$1.72M

SNWV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$9.33M	$10.05M	$11.45M	$13.09M	$9.62M	$9.74M
Cost of Revenue	$1.96M	$2.21M	$2.53M	$3.39M	$2.19M	$2.31M
Gross Profit	$7.38M	$7.85M	$8.93M	$9.70M	$7.43M	$7.42M
Research & Development	$208.00K	$194.00K	$345.00K	$606.00K	$660.00K	$628.00K
Selling, General & Admin	$6.37M	$6.04M	$6.89M	$8.19M	$7.65M	$6.83M
Operating Expenses	$6.77M	$6.41M	$7.46M	$9.09M	$8.55M	$7.70M
Operating Income	$601.00K	$1.44M	$1.47M	$615.00K	-$1.12M	-$280.00K
EBITDA	-$3.94M	$2.79M	$12.27M	$7.64M	-$581.00K	$193.00K
Pretax Income	-$6.12M	$551.00K	$10.32M	$6.20M	-$1.44M	-$676.00K
Income Tax	—	$0.00	—	—	—	$6.00K
Net Income	-$6.12M	$551.00K	$10.32M	$6.11M	-$1.44M	-$682.00K
Diluted EPS	-0.72	-0.04	0.46	—	-0.17	-0.08
Diluted Shares	8.55M	9.17M	9.14M	—	8.59M	8.60M

SNWV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$8.50M	$8.50M	$9.60M	$11.96M	$10.78M	$9.38M
Receivables	$3.87M	$3.85M	$4.62M	$5.42M	$6.00M	$5.80M
Inventory	$5.46M	$5.91M	$6.81M	$5.93M	$5.90M	$7.07M
Current Assets	$18.83M	$20.17M	$22.63M	$24.63M	$23.96M	$23.20M
Total Assets	$30.86M	$33.05M	$35.60M	$37.34M	$37.10M	$36.60M
Current Liabilities	$47.27M	$46.50M	$19.58M	$17.85M	$18.30M	$18.17M
Long-Term Debt	—	—	$17.73M	$16.32M	$14.98M	$13.58M
Total Debt	$26.87M	$27.96M	$24.45M	$22.97M	$22.16M	$20.71M
Total Liabilities	$48.15M	$47.82M	$38.53M	$35.72M	$35.26M	$33.82M
Retained Earnings	-$257.10M	-$256.04M	-$245.72M	-$242.69M	-$244.12M	-$244.81M
Shareholders' Equity	-$17.29M	-$14.78M	-$2.93M	$1.62M	$1.84M	$2.79M
Working Capital	-$28.44M	-$26.33M	$3.06M	$6.78M	$5.65M	$5.03M
Net Debt	$17.54M	$18.28M	$13.76M	$10.00M	$9.79M	$9.80M

SNWV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.52M	$993.00K	$1.08M	$3.32M	$397.00K	$425.00K
Capital Expenditure	-$162.00K	-$1.16M	-$525.00K	-$96.00K	-$158.00K	-$447.00K
Free Cash Flow	-$1.68M	-$166.00K	$556.00K	$3.22M	$239.00K	-$22.00K
Depreciation & Amortisation	$274.00K	$299.00K	$61.00K	$649.00K	$312.00K	$351.00K
Stock-Based Compensation	$975.00K	$1.13M	$1.41M	$1.34M	$1.61M	$1.53M
Investing Cash Flow	-$162.00K	-$1.16M	$4.47M	$279.00K	-$158.00K	-$448.00K
Financing Cash Flow	-$57.00K	$161.00K	-$4.45M	-$1.24M	-$1.42M	-$1.38M
Net Change in Cash	-$1.74M	-$5.00K	$1.11M	$2.36M	-$1.18M	-$1.40M

Market Snapshot

About

SANUWAVE Health is a medical device company focused on the development and commercialization of noninvasive, biological treatments for wound healing and pain reduction. The companys lead product, dermaPACE, uses pulsed acoustic waves to activate healing processes in chronic wounds. SANUWAVE markets its technology for diabetic foot ulcers and other difficult-to-heal wounds.